Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDE | P14735 | 1/20 | 0.66 |
| ▸ | UBE2N | P61088 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 8/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1256779 | 0.85 | TACR1 (0.62) | TACR1 | |
| SCHEMBL1512947 | 0.85 | TACR1 (0.62) | TACR1 | |
| SCHEMBL7829090 | 0.85 | TACR1 (0.62) | TACR1 | |
| Hydrochloric Acid SCHEMBL7823102 | 0.85 | TACR1 (0.61) | TACR1 | |
| Hydrochloric Acid SCHEMBL8487330 | 0.85 | TACR1 (0.61) | TACR1 | |
| SCHEMBL7823087 | 0.84 | TACR1 (0.66) | IDEUBE2NTACR1MITFCA1 | |
| SCHEMBL7463845 | 0.84 | TACR1 (0.52) | IDEUBE2NTACR1MITFCA1 | |
| SCHEMBL8478086 | 0.84 | IDE (0.49) | IDEUBE2NTACR1MITFCA1 | |
| Hydrochloric Acid SCHEMBL7815870 | 0.84 | IDE (0.47) | IDEUBE2NTACR1MITFCA1 | |
| SCHEMBL7122736 | 0.84 | IDE (0.49) | IDEUBE2NTACR1MITFCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0873320-B1 | PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
| US-6087357-A | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | PKD2, SSTR5, TAC3 | IDE 3071/4885UBE2N 4365/4885ATM 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.